Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-07-17 | ONCS | Oncosec Medical Inc | Alpha Holdings, Inc. | Dir, 10% | P - Purchase | $2.57 | +30,000 | 1,611,000 | +2% | +$77,100 | ||||||
| D | 2019-07-17 | MRTX | Mirati Therapeutics, Inc. | Boxer Capital, LLC | 10% | S - Sale+OE | $98.30 | -725,008 | 1,715,560 | -30% | -$71,268,328 | |||||
| M | 2019-07-17 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.33 | +6,000 | 7,037,737 | 0% | +$1,990 | |||||
| M | 2019-07-17 | KALV | Kalvista Pharmaceuticals, Inc. | Cha Albert | Dir | P - Purchase | $17.79 | +61,280 | 1,420,429 | +5% | +$1,090,296 | |||||
2019-07-19 | APVO | Aptevo Therapeutics Inc. | El-Hibri Fuad | Dir, 10% | P - Purchase | $0.90 | +26,460 | 929,521 | +3% | +$23,740 | ||||||
| M | 2019-07-17 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $10.33 | -10,800 | 2,615,942 | 0% | -$111,578 | |||||
2019-07-17 | CARA | Cara Therapeutics, Inc. | Menzaghi Frederique Ph.D. | Chief Scientific Off,SVP-R, D | S - Sale | $27.50 | -8,996 | 119,886 | -7% | -$247,390 | ||||||
| M | 2019-07-11 | CPIX | Cumberland Pharmaceuticals Inc | Bernard Gordon R | Dir | S - Sale | $5.77 | -7,471 | 53,102 | -12% | -$43,117 | |||||
2019-07-17 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale | $71.45 | -8,000 | 399,230 | -2% | -$571,616 | ||||||
| D | 2019-07-16 | BPMC | Blueprint Medicines Corp | Haviland Kate | COO | S - Sale+OE | $95.47 | -1,571 | 15,865 | -9% | -$149,989 | |||||
2019-07-16 | MACK | Merrimack Pharmaceuticals Inc | Aryeh Jason | See Explanation of Responses, 10% | P - Purchase | $5.44 | +302 | 3,802 | +9% | +$1,643 | ||||||
| D | 2019-07-17 | RARX | Ra Pharmaceuticals, Inc. | Read Simon | Chief Scientific Officer | S - Sale+OE | $32.95 | -10,000 | 6,234 | -62% | -$329,479 | |||||
2019-07-18 | APVO | Aptevo Therapeutics Inc. | El-Hibri Fuad | Dir, 10% | P - Purchase | $0.87 | +14,404 | 903,061 | +2% | +$12,596 | ||||||
2019-07-17 | APVO | Aptevo Therapeutics Inc. | El-Hibri Fuad | Dir, 10% | P - Purchase | $0.87 | +19,136 | 888,657 | +2% | +$16,704 | ||||||
| M | 2019-07-16 | ORMP | Oramed Pharmaceuticals Inc. | Sank Leonard | Dir | P - Purchase | $3.59 | +54,517 | 567,013 | +11% | +$195,711 | |||||
| M | 2019-07-15 | ONCS | Oncosec Medical Inc | Alpha Holdings, Inc. | Dir, 10% | P - Purchase | $2.30 | +90,000 | 1,581,000 | +6% | +$207,000 | |||||
| D | 2019-07-16 | CHMA | Chiasma, Inc | Mamluk Roni | Dir | S - Sale+OE | $6.35 | -10,000 | 0 | -100% | -$63,500 | |||||
| M | 2019-07-15 | SYRS | Syros Pharmaceuticals, Inc. | Arch Venture Fund Vii, L.P. | 10% | S - Sale | $7.77 | -63,000 | 4,242,051 | -1% | -$489,280 | |||||
2019-07-15 | KALV | Kalvista Pharmaceuticals, Inc. | Crockett Thomas Andrew | CEO | S - Sale | $17.04 | -10,000 | 248,510 | -4% | -$170,407 | ||||||
| M | 2019-07-15 | NGM | Ngm Biopharmaceuticals Inc | Goeddel David V | Dir, 10% | P - Purchase | $13.72 | +20,088 | 15,936,063 | 0% | +$275,603 | |||||
| M | 2019-07-15 | NGM | Ngm Biopharmaceuticals Inc | Svennilson Peter | Dir, 10% | P - Purchase | $13.72 | +20,088 | 15,766,063 | 0% | +$275,603 | |||||
| M | 2019-07-15 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | 10% | P - Purchase | $13.72 | +20,088 | 15,761,063 | 0% | +$275,603 | |||||
| D | 2019-07-15 | CARA | Cara Therapeutics, Inc. | Mohindru Mani | CFO, Chief Strategy Officer | S - Sale+OE | $25.00 | -37,431 | 13,863 | -73% | -$935,775 | |||||
2019-07-15 | AKCA | Akcea Therapeutics, Inc. | Boyce Sarah | Pres | S - Sale | $23.52 | -1,819 | 19,888 | -8% | -$42,783 | ||||||
| D | 2019-07-15 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale+OE | $94.98 | -830 | 0 | -100% | -$78,833 | |||||
2019-07-15 | COLL | Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Dir | S - Sale | $11.26 | -25,000 | 132,069 | -16% | -$281,500 | ||||||
| D | 2019-07-15 | ZTS | Zoetis Inc. | Lewis Clinton A. Jr. | EVP | S - Sale+OE | $113.09 | -6,123 | 40,689 | -13% | -$692,450 | |||||
2019-07-15 | EIDX | Eidos Therapeutics, Inc. | Fox Jonathan C | See Remarks | S - Sale | $40.04 | -15,000 | 504,377 | -3% | -$600,561 | ||||||
| D | 2019-07-15 | RETA | Reata Pharmaceuticals Inc | Wilson Jason Douglas | CFO | S - Sale+OE | $84.64 | -4,000 | 0 | -100% | -$338,556 | |||||
2019-07-16 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $2.12 | +50,000 | 217,521,633 | 0% | +$105,981 | ||||||
| D | 2019-07-12 | CTLT | Catalent, Inc. | Littlejohns Barry | Pres, Biologics, SDD | S - Sale+OE | $53.53 | -15,940 | 37,718 | -30% | -$853,344 | |||||
| D | 2019-07-15 | RARX | Ra Pharmaceuticals, Inc. | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $33.10 | -10,595 | 7,132 | -60% | -$350,647 | |||||
2019-07-15 | HROW | Harrow Health, Inc. | Kammer Robert J | Dir | S - Sale | $7.91 | -6,500 | 823,327 | -1% | -$51,415 | ||||||
| M | 2019-07-12 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $10.93 | -10,490 | 2,626,742 | 0% | -$114,662 | |||||
| M | 2019-07-12 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.33 | +7,000 | 7,031,737 | 0% | +$2,285 | |||||
2019-07-16 | APVO | Aptevo Therapeutics Inc. | El-Hibri Fuad | Dir, 10% | P - Purchase | $0.85 | +11,375 | 869,521 | +1% | +$9,662 | ||||||
2019-07-15 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $10.94 | -6,000 | 260,188 | -2% | -$65,632 | ||||||
2019-07-15 | DOVA | Dova Pharmaceuticals Inc. | Hoitt Jason | Chief Commercial Officer | S - Sale | $15.26 | -7,580 | 12,357 | -38% | -$115,664 | ||||||
| M | 2019-07-10 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.02 | +59,700 | 24,762,797 | 0% | +$921 | |||||
| M | 2019-07-11 | EYEG | Eyegate Pharmaceuticals Inc | Romano Sarah | CFO | S - Sale | $0.24 | -19,750 | 262,113 | -7% | -$4,669 | |||||
| M | 2019-07-11 | EYEG | Eyegate Pharmaceuticals Inc | Manzo Michael P. | VP of Engineering | S - Sale | $0.24 | -19,750 | 174,796 | -10% | -$4,669 | |||||
| M | 2019-07-11 | EYEG | Eyegate Pharmaceuticals Inc | Wirostko Barbara | Chief Medical Officer | S - Sale | $0.24 | -19,463 | 465,449 | -4% | -$4,601 | |||||
| M | 2019-07-11 | EYEG | Eyegate Pharmaceuticals Inc | From Stephen | Pres, CEO | S - Sale | $0.24 | -127,355 | 1,032,465 | -11% | -$30,107 | |||||
| M | 2019-07-11 | EYEG | Eyegate Pharmaceuticals Inc | Mann Brenda | VP of Research, Development | S - Sale | $0.24 | -19,049 | 174,424 | -10% | -$4,503 | |||||
| M | 2019-07-11 | NGM | Ngm Biopharmaceuticals Inc | Goeddel David V | Dir, 10% | P - Purchase | $13.88 | +31,884 | 15,915,975 | 0% | +$442,516 | |||||
| M | 2019-07-11 | NGM | Ngm Biopharmaceuticals Inc | Svennilson Peter | Dir, 10% | P - Purchase | $13.88 | +31,884 | 15,745,975 | 0% | +$442,516 | |||||
| M | 2019-07-11 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | 10% | P - Purchase | $13.88 | +31,884 | 15,740,975 | 0% | +$442,516 | |||||
2019-07-11 | ORMP | Oramed Pharmaceuticals Inc. | Sank Leonard | Dir | P - Purchase | $3.22 | +1,320 | 512,496 | 0% | +$4,250 | ||||||
| D | 2019-07-11 | CTLT | Catalent, Inc. | Fasman Steven L | SVP, GC | S - Sale+OE | $54.04 | -4,053 | 48,528 | -8% | -$219,024 | |||||
| D | 2019-07-11 | EYEN | Eyenovia, Inc. | Mario Ernest | Dir | P - Purchase | $2.78 | +35,971 | 272,741 | +15% | +$99,999 | |||||
| D | 2019-07-11 | EYEN | Eyenovia, Inc. | Labelle Curt H | Dir | P - Purchase | $2.78 | +17,985 | 1,087,985 | +2% | +$49,998 | |||||
| D | 2019-07-11 | EYEN | Eyenovia, Inc. | Ianchulev Tsontcho | CEO, 10% | P - Purchase | $2.78 | +233,813 | 1,492,248 | +19% | +$650,000 | |||||
| M | 2019-07-11 | MACK | Merrimack Pharmaceuticals Inc | Aryeh Jason | See Explanation of Responses, 10% | P - Purchase | $5.68 | +3,500 | 3,500 | New | +$19,895 | |||||
2019-07-11 | BHC | Bausch Health Companies Inc. | Ackermann Christina | EVP, GC | S - Sale | $24.81 | -3,968 | 61,722 | -6% | -$98,446 | ||||||
| D | 2019-07-12 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale+OE | $175.27 | -2,125 | 35,003 | -6% | -$372,455 | |||||
2019-07-15 | SNSS | Sunesis Pharmaceuticals Inc | Aisling Capital Iv, LP | 10% | P - Purchase | $0.60 | +2,500,000 | 10,100,000 | +33% | +$1,500,000 | ||||||
2019-07-15 | LLY | Lilly Eli & Co | Smiley Joshua L | SVP, CFO | P - Purchase | $108.47 | +185 | 32,612 | +1% | +$20,067 | ||||||
2019-07-12 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $2.16 | +50,000 | 217,471,633 | 0% | +$107,788 | ||||||
| D | 2019-07-11 | AMRN | Amarin Corp Plcuk | Stack David M | Dir | S - Sale+OE | $22.28 | -51,991 | 0 | -100% | -$1,158,354 | |||||
2019-07-11 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale | $11.26 | -1,500 | 126,567 | -1% | -$16,890 | ||||||
2019-07-10 | AMPH | Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | Pres, GC | S - Sale | $20.31 | -6,615 | 154,443 | -4% | -$134,333 | ||||||
| D | 2019-07-10 | NKTR | Nektar Therapeutics | Labrucherie Gil M | SVP, CFO | S - Sale+OE | $34.57 | -25,000 | 127,935 | -16% | -$864,250 | |||||
| M | 2019-04-05 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $6.23 | +1,554 | 5,554 | +39% | +$9,677 | |||||
| M | 2019-06-27 | CPIX | Cumberland Pharmaceuticals Inc | Bernard Gordon R | Dir | S - Sale | $6.28 | -14,376 | 60,573 | -19% | -$90,286 | |||||
| DM | 2019-07-10 | FGEN | Fibrogen Inc | Neff Thomas B | CEO | S - Sale+OE | $44.97 | -39,636 | 2,529,700 | -2% | -$1,782,614 | |||||
| DM | 2019-07-10 | FGEN | Fibrogen Inc | Chung Christine | SVP, China Operations | S - Sale+OE | $44.97 | -11,250 | 151,570 | -7% | -$505,868 | |||||
2019-07-11 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale | $12.31 | -2,857 | 37,739 | -7% | -$35,170 | ||||||
| D | 2019-07-10 | EIDX | Eidos Therapeutics, Inc. | Siu Christine | CFO, Secretary | S - Sale+OE | $39.37 | -5,000 | 36,470 | -12% | -$196,850 | |||||
| D | 2019-07-10 | KURA | Kura Oncology, Inc. | Gualberto Antonio | Head of Development, CMO | S - Sale+OE | $21.11 | -18,000 | 339,973 | -5% | -$379,903 | |||||
2019-07-11 | APVO | Aptevo Therapeutics Inc. | El-Hibri Fuad | Dir, 10% | P - Purchase | $0.85 | +14,691 | 858,146 | +2% | +$12,454 | ||||||
| D | 2019-07-10 | GWPH | Gw Pharmaceuticals Plc | Waldegrave William A. | Dir | S - Sale+OE | $15.00 | -3,576 | 0 | -100% | -$53,640 | |||||
2019-07-09 | GWPH | Gw Pharmaceuticals Plc | Snyder Douglas B. | GC | S - Sale | $14.42 | -4,968 | 82,920 | -6% | -$71,639 | ||||||
| M | 2019-07-09 | DOVA | Dova Pharmaceuticals Inc. | Perceptive Advisors LLC | 10% | P - Purchase | $16.68 | +85,104 | 3,708,705 | +2% | +$1,419,612 | |||||
| M | 2019-07-09 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $11.58 | -13,212 | 2,637,232 | 0% | -$152,955 | |||||
| M | 2019-07-09 | ONTX | Onconova Therapeutics, Inc. | Tyndall Capital Partners L P | 10% | S - Sale | $2.83 | -10,927 | 802,507 | -1% | -$30,901 | |||||
2019-07-09 | FIXX | Homology Medicines, Inc. | Rasty Siyamak | COO | S - Sale | $20.00 | -8,000 | 222,707 | -3% | -$160,000 | ||||||
2019-07-10 | APVO | Aptevo Therapeutics Inc. | El-Hibri Fuad | Dir | P - Purchase | $0.85 | +18,919 | 843,455 | +2% | +$16,058 | ||||||
| D | 2019-07-08 | FGEN | Fibrogen Inc | Kurkijarvi Kalevi | Dir | S - Sale+OE | $42.59 | -6,000 | 28,400 | -17% | -$255,570 | |||||
| M | 2019-07-08 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.31 | +8,000 | 7,024,737 | 0% | +$2,500 | |||||
2019-07-10 | ARPO | Aerpio Pharmaceuticals, Inc. | Gardner Joseph H. | Pres | P - Purchase | $0.81 | +5,000 | 603,019 | +1% | +$4,074 | ||||||
| D | 2019-07-08 | NKTR | Nektar Therapeutics | Lingnau Lutz | Dir | S - Sale+OE | $34.63 | -10,000 | 23,200 | -30% | -$346,300 | |||||
2019-07-08 | PCRX | Pacira Biosciences, Inc. | Stack David M | CEO, COB | S - Sale | $42.88 | -13,115 | 176,103 | -7% | -$562,377 | ||||||
| M | 2019-06-28 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.02 | +275,000 | 24,703,097 | +1% | +$4,437 | |||||
| D | 2019-07-08 | BPMC | Blueprint Medicines Corp | Boral Anthony L. | Chief Medical Officer | S - Sale+OE | $93.88 | -10,000 | 0 | -100% | -$938,756 | |||||
2019-07-08 | YMAB | Y-Mabs Therapeutics, Inc. | Gad Thomas | Pres, COB | S - Sale | $22.40 | -4,000 | 1,942,557 | 0% | -$89,592 | ||||||
| D | 2019-07-05 | TCDA | Tricida, Inc. | Veitinger Klaus R Dr | Dir | S - Sale+OE | $36.30 | -3,492 | 159,603 | -2% | -$126,749 | |||||
| DM | 2019-07-05 | TCDA | Tricida, Inc. | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $35.22 | -4,700 | 14,806 | -24% | -$165,549 | |||||
| M | 2019-07-05 | TCDA | Tricida, Inc. | Klaerner Gerrit | Pres, CEO | S - Sale | $35.55 | -5,826 | 762,392 | -1% | -$207,097 | |||||
| M | 2019-07-05 | TCDA | Tricida, Inc. | Coufal Sandra I | Dir, 10% | S - Sale | $35.92 | -2,000 | 7,134,427 | 0% | -$71,836 | |||||
2019-07-05 | DOVA | Dova Pharmaceuticals Inc. | Perceptive Advisors LLC | 10% | P - Purchase | $16.46 | +50,000 | 3,632,601 | +1% | +$823,000 | ||||||
2019-07-08 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $126.87 | -3,106 | 64,505,685 | 0% | -$394,055 | ||||||
2019-07-05 | WVE | Wave Life Sciences Ltd. | Panzara Michael A. | Chief Medical Officer | S - Sale | $26.94 | -3,058 | 42,330 | -7% | -$82,368 | ||||||
| D | 2019-07-05 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $44.74 | -15,312 | 29,524 | -34% | -$685,097 | |||||
| D | 2019-07-05 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale+OE | $179.12 | -4,250 | 35,003 | -11% | -$761,239 | |||||
| D | 2019-07-09 | VTVT | Vtv Therapeutics Inc. | Perelman Ronald O | 10% | P - Purchase | $1.65 | +1,212,121 | 20,276,593 | +6% | +$2,000,000 | |||||
2019-07-08 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $2.23 | +100,000 | 217,421,633 | 0% | +$222,831 | ||||||
2019-07-03 | EIDX | Eidos Therapeutics, Inc. | Satvat Ali J. | Dir, 10% | P - Purchase | $29.90 | +882,353 | 24,575,501 | +4% | +$26,382,796 | ||||||
2019-07-03 | EIDX | Eidos Therapeutics, Inc. | Kumar Neil | CEO, 10% | P - Purchase | $29.90 | +882,353 | 24,575,501 | +4% | +$26,382,796 | ||||||
2019-07-03 | EIDX | Eidos Therapeutics, Inc. | Aguiar Eric | Dir, 10% | P - Purchase | $29.90 | +882,353 | 24,575,501 | +4% | +$26,382,796 | ||||||
2019-07-03 | EIDX | Eidos Therapeutics, Inc. | Bridgebio Pharma, Inc. | 10% | P - Purchase | $29.90 | +882,353 | 24,575,501 | +4% | +$26,382,796 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |